

Targeted Chemo-Sonodynamic Therapy Treatment of Breast Tumours Using Ultrasound Responsive Microbubbles Loaded with Paclitaxel, Doxorubicin and Rose Bengal.

Keiran Logan¹, Federica Foglietta¹, Heather Nesbitt¹, Yingjie Sheng¹, Thomas McKaig¹, Sukanta Kamila¹, Jinhui Gao¹, Nikolitsa Nomikou², Bridgeen Callan¹, Anthony P. McHale¹ and John F. Callan¹.

1. Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, U.K. BT52 1SA. 2. Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, UK.

Abstract: Mastectomy is a common surgical treatment used in the management of breast cancer but has associated physical and psychological consequences for the patient. Breast conservation surgery (BCS) is an alternative to mastectomy but is only possible when the tumour is of an appropriate size. Neo-adjuvant chemotherapy has been successfully used to downstage tumours and increase the number of patients eligible for BCS. However, the chemotherapies used in this approach are non-targeted and often result in significant side effects to the patient. In this manuscript, we evaluate the potential of ultrasound targeted microbubble destruction (UTMD) to deliver Rose Bengal-mediated sonodynamic therapy (SDT) in combination with paclitaxel (PTX) and doxorubicin (Dox) chemotherapy as a potential treatment for breast cancer. Efficacy of the combined treatment was determined in a three-dimensional (3D) spheroid model of human breast cancer and in a murine model of the disease bearing subcutaneous MCF-7 tumours. The results demonstrated a significant reduction in both the cell viability of spheroids and tumour volume following treatment with the drug loaded microbubbles and ultrasound compared to targets treated with the drug loaded microbubbles alone or a Cremophor EL suspension of PTX and Dox. In addition, the weight of animals that received the microbubble treatment was unchanged throughout the study while a reduction of 12.1% was observed for animals treated with a Cremophor suspension of

PTX/Dox. These results suggest that UTMD-mediated chemo-sonodynamic therapy is an efficacious and well tolerated approach for the treatment of breast cancer.

Keywords: Chemotherapy, sonodynamic therapy, microbubbles, ultrasound targeted microbubble destruction, breast cancer, MCF-7.

1.0 Introduction: Breast cancer is the most prevalent form of cancer worldwide with 55,200 new cases reported in the UK alone in 2015.¹ Mastectomy is a common treatment for breast cancer with approximately 19,000 mastectomy surgeries performed in the UK each year.² As the physical and psychological effects of this treatment can be considerable, there is a growing need for more effective non-surgical treatments to reduce the overall mastectomy rate. Neoadjuvant chemotherapy has been used to downstage tumours in advance of surgery and enable their removal by less invasive lumpectomy.^{3,4} This approach has proven effective in increasing the number of patients eligible for breast conserving surgery without posing a risk to the overall or progression-free survival rate.⁵ However, the chemotherapies used in these regimens are non-targeted to tumour tissue and cause significant off-target effects.⁶

Ultrasound targeted microbubble destruction (UTMD) has emerged as a promising strategy for the site-specific delivery of drug payloads to solid tumours.⁷ Microbubbles (MB) are lipid or polymer stabilised gas filled microspheres that have found clinical use as contrast agents in diagnostic ultrasound (US) applications. At low acoustic pressures, the MBs resonate in a symmetric manner and this feature helps improve the quality of the US image.⁸ At higher acoustic pressures, inertial forces dominate resulting in microbubble collapse and ultimately destruction of the MB.⁹ When drug payloads are incorporated within the MB structure, they become deposited at the site of destruction.⁸ As US energy can be tightly focussed in three dimensions in human tissue, it is therefore possible to use UTMD to selectively deliver payloads to target sites with limited damage to surrounding tissue.⁹

We have previously demonstrated in pre-clinical experiments the utility of UTMD as an effective strategy for the delivery of chemotherapy and sonodynamic therapy (SDT) to pancreatic tumours.¹⁰ SDT is an emerging cancer treatment and involves the activation of an otherwise harmless sensitiser drug with low-intensity US to generate cytotoxic levels of reactive oxygen species (ROS).¹¹⁻¹⁴ As oxygen is a key substrate for the generation of ROS in SDT, we have demonstrated that filling the core of MBs with oxygen gas enhances the ROS yield and SDT mediated cytotoxic effect observed.¹⁵ Our previous work has also shown that combining SDT with antimetabolite chemotherapy is more effective than either treatment alone at controlling the growth of pancreatic tumours.^{10, 16} Moreover, by using UTMD as a drug delivery strategy, it was possible to achieve targeted delivery to the tumours and significantly reduce the overall amount of chemotherapy administered.

In this study, we adopted a similar approach using MBs to facilitate delivery of chemo-sonodynamic therapy for the treatment of breast cancer. Doxorubicin (Dox) and paclitaxel (PTX), which are commonly used in the management of breast cancer, were selected as chemotherapies while Rose Bengal (RB) was used as the SDT sensitiser. PTX is a notoriously hydrophobic drug with a LogP of approximately 3.5¹⁷ and was incorporated within the hydrophobic acyl chain layer of the MB shell, while the hydrophilic Dox was modified to include a biotin anchor that enabled its attachment to the MB surface using the biotin-avidin interaction. As in our previous work, a biotin derivative of RB was also prepared to facilitate attachment to the MB surface.¹¹ The resulting MBs were characterised in terms of size, concentration and drug loading while the efficacy of MB mediated chemo-sonodynamic therapy was determined in a three-dimensional (3D) spheroid model of human breast cancer and in a murine model of the disease bearing subcutaneous MCF-7 tumours.

2.0 Materials & Methods.

2.1 Reagents and Materials: 1,2-dibehenoyl-*sn*-glycero-3-phosphocholine (DBPC) and 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000)) and DSPE-PEG(2000)-biotin were purchased from Avanti Polar Lipids

(Alabaster, Alabama, USA). Avidin (Egg White) was purchased from Thermo Fisher Scientific (Waltham, Massachusetts, USA). Oxygen and nitrogen gas was purchased from BOC Industrial Gases (Guildford, UK) and perfluorobutane (PFB) was purchased from Apollo Scientific Ltd (Cheshire, UK). Phosphate Buffered Saline (PBS), streptomycin, Dulbecco's Modified Eagle's Medium (DMEM) and Propidium Iodide (P.I.) were purchased from Thermo Fisher Scientific (Massachusetts, USA). Matrigel was purchased from Corning (New York, USA). Severe combined immunodeficient (SCID) (C.B-17/lcrHan^{Hsd-Prkdcscid}) mice were purchased from Charles River Laboratory (Massachusetts, USA). Paclitaxel and biotin were purchased from XABC (Xi'an, China). Doxorubicin was purchased from LC Laboratories (Boston, MA, USA). All other chemicals were purchased from Sigma Aldrich (Gillingham, UK) at the highest grade possible. MCF-7 cells were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). CellCarrier Ultra ULA-Coated 96-well Microplates were purchased from Perkin Elmer (Massachusetts, USA). Analytical HPLC analysis was undertaken using a Shimadzu HPLC (Shimadzu, Kyoto, Japan) fitted with an SPD-M20A photo-diode array detector and a Phenomenex C₁₈ column (Phenomenex, California, USA) (250 × 4.6 mm, 5 μm). UV-Vis analysis was performed using a Varian-50 Bio UV-Visible spectrophotometer (Varian, California, USA). Optical microscope images were obtained using a Leica DM500 optical microscope (Leica, Wetzlar, Germany). MTT absorbance was analysed using a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany). Fluorescence images were obtained using a NIKON Eclipse E400 Phase contrast microscope (Nikon, Tokyo, Japan) (540 nm band pass excitation and 590 nm long pass emission filters, respectively). NMR spectra were recorded on a Varian 500 MHz spectrometer (Varian, California, USA). ESI-MS characterisation was achieved using a LCQTM quadrupole ion-trap mass spectrometer (Finnigan MAT, California, USA) utilising electrospray ionisation (ESI).

2.2 Synthesis of Biotin-Dox (5): Biotin-N-hydroxysuccinimide ester (**3**) was prepared by the reaction of biotin (**1**) and N,N-Disuccinimidyl carbonate (**2**) following a literature procedure.¹⁸ To an ice cold solution of **3**, (0.14g, 0.41 mmol) in DMF (10 ml) was added doxorubicin (**4**,

0.3g, 0.41mmol) under a nitrogen atmosphere. After stirring for 30 min, triethylamine (0.5 ml, 2 mmol) was added to the reaction mixture and the contents stirred for 12 h at room temperature. The reaction was monitored by **thin layer chromatography** (TLC) (Merck Silica 60, HF 254, 20: 80 methanol-dichloromethane v/v). After completion of the reaction, excess diethyl ether (100 ml) was added to the reaction mixture. The resultant red precipitate was filtered and washed three times with diethyl ether (50 ml X 3). The solid was then subjected to **preparative thin layer chromatography** (PTLC) purification (methanol-dichloromethane (20:80, v/v)) to obtain 0.25g (Yield = 78%) of **5**. ¹H NMR (DMSO-d₆) δ : 7.84 (d, J = 7.5 Hz, 2H, aromatic), 7.58 (d, J = 7.5 Hz, 1H, aromatic), 6.36 (s, 1H, NH), 6.29 (s, 1H, NH), 5.37 (brs, 1H, OH), 5.22 (brs, 1H, OH), 4.87 (s, 2H, -CH₂-OH), 4.51 (brs, 2H, OH X 2), 4.36-4.33 (m, 1H, CH), 4.25-4.22 (m, 1H, CH), 4.16-4.13 (m, 1H, CH), 3.99 (s, 3H, OCH₃), 3.60-3.58 (m, 1H, CH), 3.55 (brs, 2H, OH X2), 3.10-3.00 (m, 4H, CH₂ X1, CH X 2), 2.88-2.54 (m, 3H, CH₂ X 1, CH), 2.20-2.00 (m, 1H, CH), 1.63-1.50 (m, 4H, CH₂ X 2), 1.42-1.22 (m, 11 H, CH₃ X 1, CH₂ X 4). ¹³CNMR (DMSO-d₆): 177.6, 176.9, 174.8, 166.4, 163.0, 161.2, 153.7, 152.7, 137.4, 132.4, 120.4, 119.4, 99.5, 97.8, 80.15, 75.1, 72.7, 66.4, 61.4, 59.5, 55.7, 47.8, 33.8, 31.9, 28.9, 28.8, 28.5, 28.4, 24.9, 19.8, 17.6, 17.1. Negative mode electrospray mass spectrum: **ESI-MS [M-H]**: calculated for C₃₇H₄₃I₂N₃O₁₃S = 769 Da, found = 768 Da.

2.3 Preparation of oxygen carrying microbubbles loaded with PTX in the shell and biotin-Dox or biotin-RB attached to the MB surface: Avidin-functionalised PTX-loaded MB were prepared by first dissolving 1,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC) (4.0mg, 4.44 μ mol), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol) -2000] (DSPE-PEG(2000)) (1.35mg, 0.481 μ mol) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG (2000)-biotin) (1.45mg, 0.481 μ mol) in chloroform to achieve a molar ratio of 82:9:9. To this solution was added paclitaxel (**7**, 5mg, 5.86 μ mol) dissolved in chloroform (100 μ L). The solvent was removed under vacuum at room temperature yielding a translucent film. The film was then reconstituted in 2mL of a solution containing PBS, glycerol

and propylene glycol (8:1:1 volume ratio) and heated in a water bath at 80°C for 30 min. The suspension was sonicated using a Microson ultrasonic cell disrupter at an amplitude of 22% for 1 min and then at an amplitude of 90% in a perflourobutane (PFB) atmosphere for 30 sec. The MBs were then cooled on ice for 10 min followed by centrifugation at 100 rcf for 3 min and the liquid laying below the surface of the MB cake (infranatant) was removed. The PTX-MB cake was then washed a further 2 times with PBS (pH 7.4 ± 0.1) before being mixed for 5 min on ice with an aqueous solution of avidin (10 mg/mL) using an orbital shaker (150 rpm). The PTX-MBs were then centrifuged (100 rcf) for 3 min, the infranant removed and the MB cake washed with PBS solution (2 mL, pH 7.4 ± 0.1) which was again removed following centrifugation. The PTX-MB cake was again reconstituted in PBS solution (2 mL, pH 7.4 ± 0.1), mixed for 5 min with an aqueous solution containing either biotin-Dox (5) or biotin-RB (6) (1mL, 5mg / mL) and centrifuged (100 rcf) for 3 min. Following removal of the infranant, the MB cake was then washed with PBS (2 mL, pH = 7.4 ± 0.1), centrifuged and the MB cake isolated. This washing / centrifugation procedure was repeated twice further with the final PTX-Dox MB / PTX-RB MB cake reconstituted in 2 mL of PBS. The final MB number was determined on a haemocytometer using an optical microscope. Size distribution analysis was carried out using imageJ image analysis software. MBs were sparged with oxygen gas for 2 min immediately prior to use. Fluorescence imaging of PTX-RB MB and PTX-DOX MB were performed using a Nikon Eclipse E400 epi-fluorescence microscope equipped and the G-2A longpass emission filter set (λ_{EX} 510–560, 80% transmission with a 590 nm cut-on wavelength of the longpass emission). The drug loading on the surface of the MBs was determined using UV–Vis spectroscopy for 5 and 6 measuring the intensity at 480nm or 560nm respectively. Samples were prepared by firstly destructing (bursting) the MB using an ultrasound bath before removing a known volume and diluting with PBS. The drug loading for 7 was determined using reverse phase HPLC, using a Phenomenex C₁₈ column (250 × 4.6 mm, 5 µm), a mobile phase consisting of acetonitrile: water (50:50 v/v), a flow rate of 1.5 mL/min–1 using 227 nm as the detection wavelength. The loading of PTX was calculated by the following equation: loading = amount of PTX loaded into the MB / total amount of lipid material x 100%.

2.4 Clonogenic assay to determine the cytotoxicity of Dox, PTX, SDT and combinations

of each in MCF-7 cells: The human breast adenocarcinoma cell line (MCF-7) was cultured in DMEM supplemented with 10% FBS, 100 µg/ml streptomycin and maintained in a humidified, 5% CO₂ atmosphere at 37°C. MCF-7 cells were seeded (5×10^3) into each well of a 96 well plate and 24 h later cells were treated with PTX (1nM), Dox (10nM), RB (10nM) or combinations thereof for 3 h, followed by medium replacement. Selected wells were treated with ultrasound for 30 s delivered using a Sonidel SP100 sonoprotator using a frequency of 1 MHz, an US power density of 3.0 W/cm² and a duty cycle of 50% (pulse frequency = 100 Hz). After 18 h, cells were pooled from 2 wells and seeded in a 6 well plate containing 5 ml of complete media. Plates were placed in an incubator for 7 days. Medium was removed from wells and fixation/staining solution (1mL) [consisting of crystal violet (0.05% w/v), formaldehyde (2.7% v/v), PBS (10% v/v), methanol (1% v/v) and distilled water (86.3% v/v)] was added to each well at room temperature for 20 min. The solution was removed and wells were washed with water. Digital photographs were taken using a Canon EOS100D DSLR and colony formation was analysed using Image J software.

2.5 Preparation of 3D MCF-7 spheroids: Spheroids were generated by growing MCF-7 cells in 96 well Carrier Plates (ULA) from PerkinElmer. Cells were seeded (8×10^3 , 100µL) in selected wells. After 24 h, 100 µl of medium was added to each well and plates were incubated at 37°C in a humidified 5% CO₂ atmosphere for a further 3 days to allow the cells to aggregate. Medium was replenished every 3 days by removing 100 µL of old media and replacing it with 100 µL of fresh media.

2.6 Chemo-sonodynamic therapy treatment of MCF-7 Spheroids using O₂MB-PTX-Dox

/ O₂MB-PTX-RB ± ultrasound: Three days after seeding, spheroids were allocated to groups and treated according to the following conditions: untreated (drug-free medium), O₂MB (no drugs), PTX/Dox only ([PTX] = 0.34 µM, [Dox] = 1 µM), and O₂MB-PTX-Dox / O₂MB-PTX-RB ([Dox] = 1 µM, [RB] = 10 µM). Where required, individual wells were then placed in direct contact with the emitting surface of a Sonidel SP100 sonoprotator with US gel used to mediate

contact. Each well was treated with US for 30 s using a frequency of 1 MHz, an US power density of 3.0 W/cm² and a duty cycle of 50% (pulse frequency = 100 Hz). Plates were incubated in a humidified 5% CO₂ atmosphere at 37 °C for 3 h and then wells were washed 3 times with PBS before fresh medium was added. 48 h after treatment, 5 spheroids per replicate from each condition were collected in an Eppendorf tube, washed with PBS and then incubated with trypsin/EDTA for 15 min at 37°C. The resultant cellular suspension was then incubated for 3 h with MTT [10 µl (5mg/mL) in 100 µl of medium). The absorbance was then measured at 570 nm using FLUOstar Omega microplate reader. Data were expressed as % cell viability by comparison with untreated controls.

In addition to MTT analysis, propidium iodide (P.I.) staining was also performed to determine cellular damage to the spheroid corona. Following treatment, spheroids were washed 4 times with PBS to remove excess medium and then incubated with a solution of P.I. in PBS (100 µg/ml). Spheroids were then incubated in the dark at RT for 40 min and then washed 3 times with PBS to remove excess P.I. Micrographic images were recorded using a NIKON Eclipse E400 Phase contrast microscope in bright field and fluorescence modes (540 nm band pass excitation and 590 nm long pass emission filters). Image J software was used to quantify P.I. fluorescence and it was expressed as a % of P.I. fluorescence intensity/µm², i.e. the P.I. fluorescence was normalized according to the area of the spheroid.

2.7 Cytotoxicity of chemo-sonodynamic therapy in vivo using O₂MB-PTX-Dox / O₂MB-PTX-RB ± ultrasound: All animals employed in this study were treated humanely and in accordance with licenced procedures under the UK Animals (Scientific Procedures) Act 1986. MCF-7 cells (5 x10⁶) in 100 µL Matrigel were sub-cutaneously implanted into the rear dorsum of 8-week old female SCID (C.B-17/IcrHan®Hsd-Prkdcscid) mice. Palpable tumours appeared approximately 1-2 weeks after cell implantation. Once tumours became palpable, dimensions were measured using Vernier callipers. Tumour volume was calculated using the equation: tumour volume = (length x width²)/2. Once tumours reached approximately 65 mm³ animals were separated into the following groups: Group 1 remained untreated, groups 2 and 3 received an intravenous (IV) injection (50 µL) of a mixed suspension of O₂MB-PTX-RB and

O₂MB-PTX-Dox (6.18x10⁷ MB, [PTX] = 1.13 ± 0.16 mg / kg, [RB] = 2.63 ± 0.35 mg / kg, [Dox] = 0.97 ± 0.15 mg / kg with (group 2) or without (group 3) ultrasound exposure. Group 4 received an I.V injection (100 µL) of a Cremophor suspension containing PTX (4.7 mg / kg) and Dox (2.5 mg / kg). Ultrasound was administered directly to the tumour site using a Sonidel SP100 sonoprotator (3.5 Wcm⁻², 1 MHz, 30% duty cycle, and PRF = 100 Hz; PNP = 0.48 MPa; M.I. = 0.48) during, and 30 min after IV administration (for a total of 7.0 min) using ultrasound gel to mediate contact. Animals were treated on days 0, 7 and 21 and both the tumour volume and body weight measurements recorded at the indicated times.

2.8 Statistical Analysis: Error was reported as ± standard error of the mean. Statistical analysis was undertaken using a GraphPad Prism software package (IBM, UK). Group-wise comparisons were made using one-sided parallel group t-tests with a p-value less than 0.05 deemed significant.

3.0 Results and Discussion: In advance of preparing and testing the drug loaded O₂MBs, we were first interested in determining the effectiveness of combining PTX, Dox and SDT on the treatment of MCF-7 cells. In this study, the concentration of each individual drug used was intentionally sub-lethal (i.e. drug concentrations that had no impact on cell viability), so that any benefit obtained by the combination treatment could easily be identified. In addition, as the action of US can influence the cellular uptake of drugs due to sonoporation, cells treated with Dox or PTX were also exposed to US, to control for any potential effects as a result of US exposure during SDT treatment.¹⁹ Following treatment, cell viability was then determined using a clonogenic assay. The results are shown in Figure 1 and reveal no reduction in colony number for cells treated with a combination of PTX, Dox and RB in the absence of US compared to untreated cells. Treatment of cells with PTX + US, RB + US (i.e. SDT) or Dox + US reduced colony number by 7.3, 18.8 and 29.3% respectively compared to untreated cells, while cells treated with combined PTX, Dox and RB + US reduced the colony number by 44.0%. The lack of efficacy for the combined drug cocktail in the absence of US was not surprising as sub-lethal doses of the drugs were used. However, the significant improvement

in efficacy following exposure to US may result from a sonoporative effect that improves the uptake of these drugs. The fact that the greatest reduction in colony number was observed for the combined PTX, Dox and SDT treatment group indicates that these three treatments complement each other and improve the overall cytotoxic effect observed.

Encouraged by these results, the next step was to incorporate the PTX, Dox and RB into the MB delivery vehicle. Two MB formulations were prepared (Figure 2): the first comprised PTX loaded in the hydrophobic acyl layer of the MB shell while biotin-Dox was attached to the MB surface using the biotin-avidin linkage (O₂MB-PTX-Dox); the second formulation also had PTX loaded in the MB shell but with biotin-RB attached to the MB surface (O₂MB-PTX-RB).

To attach RB and Dox to the O₂MB surface it was necessary to modify each compound to contain biotin functionality. We have described the preparation of biotin-RB before in a previous communication.¹¹ However, the preparation of biotin-Dox has not yet been reported and was synthesised according to Scheme 1. Briefly, biotin (**1**) was first reacted with *N,N'*-disuccinimidyl carbonate (**2**) to form the corresponding NHS activated ester (**3**). Dox (**4**) was then attached to **3** via an amidation reaction to form the target compound biotin-Dox (**5**) which was isolated following preparative TLC purification and its structure confirmed using NMR and mass spectroscopy.

Following their preparation, O₂MB-PTX-Dox and O₂MB-PTX-RB were characterised using optical and fluorescence microscopy (Figure 3) while the drug loading was determined using UV-Vis spectroscopy (for RB and Dox) and HPLC (for PTX). Analysis of optical microscope images confirmed the presence of spherical O₂MB-PTX-Dox and O₂MB-PTX-RB microbubbles with mean particle diameters of 2.82 ± 0.05 and 2.61 ± 0.02 μm respectively and mean microbubble concentrations of 1.2 × 10⁹ and 1.35 × 10⁹ MB / mL respectively. Both O₂MB-PTX-Dox and O₂MB-PTX-RB also exhibited bright red fluorescent shells when analysed using fluorescent microscopy consistent with the successful attachment of the inherently fluorescent Dox and RB respectively (Figure 3). The mean loading of PTX, Dox and

RB onto the MBs was determined to be $51.8 \pm 8.3 \mu\text{g} / 10^8 \text{ MBs}$, $41.3 \pm 2.6 \mu\text{g} / 10^8 \text{ MBs}$ and $140.0 \pm 23.4 \mu\text{g} / 10^8 \text{ MBs}$ respectively. This reflects a loading for PTX of $23.5 \pm 1.8 \%$ which compares favourably with previous studies where PTX was loaded hydrophobically within the MB shell.^{20, 21} One potential complication of loading PTX in the MB shell is that it could compromise the subsequent loading of biotinylated payloads to the MB surface. To determine if this was the case, batches of MBs with or without PTX in the shell were prepared and the ability to attach biotin-RB to the surface determined. The results are shown in Figure 4 and reveal no significant change in the loading of biotin-RB in the absence or presence of PTX. Indeed, the loadings achieved for both PTX and DOX using the approach adopted in this study suggest it would be possible to deliver clinically relevant doses of both agents PTX ($175\text{mg}/\text{m}^2$) and DOX ($25\text{mg}/\text{m}^2$) as a part of the MB platform whilst remaining within the tolerated MB dose determined in primates (i.e. 3.31×10^{11} MBs to deliver $175\text{mg}/\text{m}^2$ PTX and 0.609×10^{11} MBs to deliver $25\text{mg}/\text{m}^2$ DOX).²² Off course, targeting delivery using UTMD means it should be possible to use much lower concentrations of these toxic chemotherapy drugs while maintaining an effective therapeutic outcome.

Having successfully prepared and characterised the O₂MB-PTX-Dox and O₂MB-PTX-RB conjugates, the next step was to determine their efficacy in a 3D spheroid model of breast cancer. This model was chosen over the more conventional two-dimensional (2D) cellular monolayer as the heterogeneous architecture of a 3D spheroid more closely resembles that of *in vivo* solid tumours and thus is a valuable tool in the screening of new drugs and drug delivery systems.²³ Spheroids were treated with O₂MB only (i.e. no drugs attached), PTX / Dox only (i.e. not MB bound) and the O₂MB-PTX-Dox / O₂MB-PTX-RB conjugates in the presence and absence of US. Untreated spheroids and spheroids treated with US only were also included for comparative purposes. Following treatment, the extent of cell viability was determined using an MTT assay and also by staining the spheroids with propidium iodide (P.I.) following treatment.

Results from the MTT assay are shown in Figure 5 and reveal a moderate reduction in the viability of cells following exposure to US alone (28.03%, $p < 0.05$), which was similar to the reduction observed for the O₂MB + US treatment (29.40 %). Treatment of PTX / Dox alone reduced viability by 21.98% ($p < 0.05$) relative to untreated spheroids, which was broadly unchanged in the presence of ultrasound (23.67%). However, when spheroids were treated with the O₂MB-PTX-Dox / O₂MB-PTX-RB conjugates and US, the cell viability decreased by 72.6% which was significantly greater than treatment with the O₂MB-PTX-Dox / O₂MB-PTX-RB conjugates in the absence of US (8.2%) or the other groups. This improved cytotoxicity is most likely due to both SDT and the ability of O₂MB induced cavitation to enhance dispersion of the drugs within the spheroid matrix.²⁴ Indeed, MB cavitation is known to create associated microstreaming and microjetting events that have been attributed to improved tumour uptake and efficacy of chemotherapy drugs in several pre-clinical and clinical studies.²⁵⁻²⁷

Results from the P.I. staining experiments revealed a slightly different trend from those obtained using the MTT assay. P.I. is a DNA selective permeable dye that passes freely through compromised plasma membranes of dead cells and does not permeate the membrane of living cells.²⁸ In contrast to the MTT assay experiments, where a single cell suspension of cells derived from spheroids was analysed post-treatment, intact spheroids were examined following treatment using P.I. staining. The brightfield and fluorescent images from each treatment group are shown in Figure 6a with the fluorescence intensity quantified and plotted in Figure 6b. Bright red P.I. fluorescence was observed for spheroids treated with the O₂MB-PTX-Dox/O₂MB-PTX-RB + US group which was significantly more intense than any of the other groups. It was also noticed that the mean volume of spheroids treated with O₂MB-PTX-Dox/O₂MB-PTX-RB + US was significantly smaller than in any of the other groups including those spheroids treated with O₂MB-PTX-Dox / O₂MB-PTX-RB in the absence of US. Combined, the intense P.I. fluorescence and size reduction observed for spheroids treated with O₂MB mediated chemo-sonodynamic therapy, in addition to the reduced cell viability

observed from the MTT assay experiments, highlight the effectiveness of this treatment in this particular model of breast cancer.

While encouraged by the results obtained from the 3D spheroid experiments, the full utility of O₂MBs as a delivery vehicle can only be determined *in vivo*. To this end, subcutaneous MCF-7 tumours were established in recipient mice and a mixed suspension of the O₂MB-PTX-Dox / O₂MB-PTX-RB formulations was administered to animals by IV injection. During injection, US was positioned at the tumour to disrupt the O₂MB, release the payloads and activate SDT, where appropriate. To evaluate the effectiveness of the O₂MB delivered treatments, a group of animals were also treated with a combination of free PTX / Dox (i.e. not O₂MB attached). The tumour growth delay plot is shown in Figure 7 and reveals a significant reduction in tumour volume for animals treated with O₂MB-PTX-Dox / O₂MB-PTX-RB + US, with tumours still 11.44% smaller than the pre-treatment size 25 days after the initial treatment. In contrast, tumours in animals treated with the same O₂MB-PTX-Dox / O₂MB-PTX-RB formulation in the absence of ultrasound increased in volume by 40.47% over the same time period. Indeed, the effect of O₂MB-PTX-Dox / O₂MB-PTX-RB + US was also significantly better than that observed following treatment using the free PTX / Dox combination which increased in volume by 18.90% at day 25, despite receiving a 16.8% and 98.4% increased dose of PTX and Dox respectively. Combined, these results corroborate the *in vitro* efficacy results and highlight the effectiveness of O₂MB delivered chemo-sonodynamic therapy as a targeted treatment for breast cancer. In addition to the improved efficacy offered by this approach, the treatment was also well tolerated with the body weight of animals in the O₂MB treated groups mapping closely to that of untreated animals. In contrast, there was a 12.1% drop in body-weight for animals treated with free PTX / Dox over the course of the experiment. This reduction in body weight most likely results from toxicity exhibited by the free drugs or the Cremophor EL vehicle required to deliver PTX. Cremophor EL is known to produce undesirable side-effects and while poorly tolerated,²⁹⁻³¹ is necessary to enable the dispersion of hydrophobic PTX in aqueous solution. Therefore, the ability to avoid the use of such a toxic

vehicle by incorporating PTX within the O₂MB shell is an added advantage of the microbubble-based drug delivery system.

In conclusion, the use of O₂MBs offer an attractive vehicle for the delivery of a chemo-sonodynamic therapy to solid breast tumours. The improved efficacy of O₂MB delivered chemo-sonodynamic therapy, when compared to standard PTX / Dox treatment was demonstrated in both *in vitro* and *in vivo* models of the disease. In particular, the reduction in tumour volume, observed following treatment with O₂MB-delivered chemo-sonodynamic therapy, offers significant potential as a neo-adjuvant therapy to downstage tumours in advance of surgery, or, as a treatment for locally recurrent chest wall disease. An added advantage of this approach is that each component part of the treatment (i.e. the MBs, PTX, Dox, RB and US) has been safely used in humans previously thus providing the opportunity for rapid clinical translation.

Acknowledgements: JFC thanks Norbrook Laboratories Ltd for an endowed chair. KL thanks the Department for the Economy in Northern Ireland for a PhD studentship.

Data Availability: The raw/processed data required to reproduce these findings cannot be shared at this time due to legal reasons.

References

1. Cancer Research UK. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer> (accessed 2 July 2018).
2. Lawrence G, Kearins O, Lagord C, Cheung S, Sidhu J, Sagar J. *The Second All Breast Cancer Report*. <http://www.ncin.org.uk/view.aspx?rid=612> (accessed 2 July 2018).
3. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. *The British Journal of Surgery* 2007; 94(10): 1189-1200.
4. Kiebert GM, de Haes JC, van de Velde CJ. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. *Journal of Clinical Oncology* 1991; 9(6): 1059-1070.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from randomised trials. *The Lancet Oncology* 2017; 19(1):27-29.
6. Perez EA. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. *Cancer Investigation* 2001; 19(2):155-164.
7. Mayer CR, Geis NA, Katus HA, Bekeredjian R. Ultrasound targeted microbubble destruction for drug and gene delivery. *Expert Opinion on Drug Delivery* 2008; 5(10):1121-1138.
8. Villarraga HR, Foley DA, Mulvagh SL. Contrast echocardiography 1996. A review. *Texas Heart Institute* 1996; 23(2):90-97.
9. Stride E, Saffari N. Microbubble ultrasound contrast agents: A review. *Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine* 2003; 217(6):429-447.

10. McEwan C, Kamila S, Owen J, Nesbitt H, Callan B, Borden M, et al. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. *Biomaterials* 2016; 80:20-32.
11. Nomikou N, Fowley C, Byrne NM, McCaughan B, McHale AP, Callan JF. Microbubble-sonosensitizer conjugates as therapeutics in sonodynamic therapy. *Chemical Communications* 2012; (67):8332-8334.
12. McCaughan B, Rouanet C, Fowley C, Nomikou N, McHale AP, McCarron PA, Callan JF. Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs. *Bioorganic and Medicinal Chemistry Letters* 2011; 21(19): 5750-5752.
13. McEwan C, Fowley C, Nomikou N, McCaughan B, McHale AP, Callan JF. Polymeric Microbubbles as Delivery Vehicles for Sensitizers in Sonodynamic Therapy. *Langmuir* 2014; 30(49): 14926–14930.
14. Sugita N, Iwase Y, Yumita N, Ikeda T, Umemura S. Sonodynamically induced cell damage using rose bengal derivative. *Anticancer Research* 2010; 30(9): 3361-3366.
15. McEwan C, Owen J, Stride E, Fowley C, Nesbitt H, Cochrane D, et al. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours. *Journal of Controlled Release* 2015; 203:51-56.
16. Nesbitt H, Sheng Y, Kamila S, Logan K, Thomas K, Callan B, et al. Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer. *Journal of Controlled Release* 2018; 279: 8-16.
17. R. M. Straubinger, "Biopharmaceutics of paclitaxel (Taxol): formulation, activity and pharmacokinetics," in *Taxol: Science and Applications*, M. Suffness, Ed., pp. 237–258, CRC Press, 1996.

18. Susumu K, Uyeda HT, Medintz IL, Pons T, Delehanty JB, Mattoussi H. Enhancing the Stability and Biological Functionalities of Quantum Dots via Compact Multifunctional Ligands. *Journal of the American Chemical Society* 2007; 129(45): 13987-13996.
19. Dimceviski G, Kotopoulis S, Bjånes T, Hoem D, Schjøtt J, Gjertsen BT, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. *Journal of Controlled Release* 2016; 243: 172-181.
20. Luo T, Sun J, Zhu S, He J, Hao L, Xiao L, et al. Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts. *Cancer Letters* 2017; 391: 1-11.
21. Xing W, Gang WZ, Yong Z, Yi ZY, Shan XC, Tao RH. Treatment of xenografted ovarian carcinoma using paclitaxel-loaded ultrasound microbubbles. *Academic Radiology* 2008; 15(12): 1574-1579.
22. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipid-coated microbubbles. *Advanced Drug Delivery Reviews* 2004; 56(9): 1291-314.
23. Wen Z, Liao Q, Hu Y, You L, Zhou L, Zhao Y. A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay. *Brazilian Journal of Medical and Biological Research* 2013; 46(7): 634-342.
24. Karshafian R, Bevan PD, Williams R, Samac S, Burns PN. Sonoporation by ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability. *Ultrasound in Medicine and Biology* 2009; 35(5): 847-60.
25. Postema M, van Wamel A, Lancée CT, de Jong N. Ultrasound-induced encapsulated microbubble phenomena. *Ultrasound in Medicine and Biology* 2004; 30(6): 827-840.

26. van Wamel A, Bouakaz A, Versluis M, de Jong N. Micromanipulation of endothelial cells: Ultrasound-microbubble-cell interaction. *Ultrasound in Medicine and Biology* 2004; 30(9): 1255–1258.
27. van Wamel A, Kooiman K, Hartevelde M, Emmer M, ten Cate FJ, Versluis M, de Jong N. Vibrating microbubbles poking individual cells: Drug transfer into cells via sonoporation. *Journal of Controlled Release* 2006; 112(2): 149-155.
28. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. *Nature Protocols* 2006; 1(3): 1458-61.
29. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). *Seminars in Oncology* 1993; 20:1-15.
30. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. *Journal of Clinical Oncology* 1994; 12(12): 2654-2666.
31. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. *Journal of the National Cancer Institute* 1998; 90 (4): 300-306.

Figures & Diagrams




Figure 1. Plot showing % of surviving MCF-7 cells for each of the treatment groups. Cells were treated with PTX +US (1nM), Dox +US (10nM), RB +US (10nM) and PTX + Dox + RB +US ([PTX] = 1nM, [Dox] = 10nM, [RB] = 10nM). After treatment, cells were incubated for 8 days followed by fixation and staining. Crystal violet staining of representative images are shown in the panel above each data bar.





Figure 2. Schematic representation of (a) O₂MB-PTX-DOX and (b) O₂MB-PTX-RB.



Scheme 1. Synthetic scheme for the synthesis of biotin-Dox (5). Also shown are the structures of biotin-RB (6) and PTX (7).




Figure 3. Representative bright field (left panel) and fluorescence (middle panel) micrographs and corresponding size distribution analyses (right panel) of (a) PTX-RB MB and (b) PTX-Dox MB.




Figure 4. Plot of Rose Bengal loading (normalized to 10^8 MBs) in the absence (0 mg) and presence (5mg) of paclitaxel incorporated within the lipid layer during MB formulation (final PTX loading = $51.8 \pm 8.3 \mu\text{g}/10^8 \text{ MB}$).




Figure 5. Plot of cell viability for 3D MCF-7 spheroids following exposure to (i) no treatment (ii) O₂MB only (no drugs), (iii) PTX/Dox only (i.e. no O₂MBs) ([PTX] = 0.34 μM, [Dox] = 1 μM) or (iv) O₂MB-PTX-Dox/O₂MB-PTX-RB ([Dox] = 1 μM, [RB] = 10 μM) in the presence or absence of US.: *p < 0.05, ***p < 0.001 for treatment groups compared to untreated group. &&p < 0.01 for O₂MB-PTX-Dox/O₂MB-PTX-RB + US v PTX/Dox + US. \$\$\$p < 0.001 for O₂MB-PTX-Dox/O₂MB-PTX-RB + US v O₂MB-PTX-Dox/O₂MB-PTX-RB – US. Error bars represent ± the standard error, n = 3.




Figure 6. (a) Optical (left panel) and fluorescence (right panel) micrographs of MCF-7 spheroids exposed to: (i) no treatment, (ii) US only (iii) MB only, (iv) O₂MB + US (v) PTX/Dox only ([PTX] = 0.34 μM, [Dox] = 1 μM), (vi) PTX / Dox + US (vii) O₂MB-PTX-Dox / O₂MB-PTX-RB ([Dox] = 1 μM, [RB] = 10 μM) and (viii) O₂MB-PTX-Dox / O₂MB-PTX-RB + US. Spheroids were stained with P.I. following treatment. (b) plot of P.I. intensity per μm² for each of the groups shown in (a) (normalized to 100% by comparison with O₂MB-PTX-Dox / O₂MB-PTX-RB + US group). *p < 0.05, **p < 0.01, ***p < 0.001 significance for treatment groups relative to untreated group. \$\$p < 0.01 significance for O₂MB-PTX-Dox/O₂MB-PTX-RB + US v O₂MB-PTX-Dox/O₂MB-PTX-RB PTX/Dox + US. &&p < 0.001 significance for O₂MB-PTX-Dox/O₂MB-PTX-RB + US v PTX/Dox + US. Error bars represent ± the standard error, n = 3.




Figure 7. (a) Tumour growth delay plot for mice bearing MCF-7 xenograft tumours. Control animals received no treatment. Groups were treated with a mixed suspension (50 μ L) of O₂MB-PTX-RB and O₂MB-PTX-Dox (6.18×10^7 MB, [PTX] = 1.13 ± 0.16 mg/kg, [RB] = 2.63 ± 0.35 mg/kg, [Dox] = 0.97 ± 0.15 mg/kg) delivered by IV in the presence and absence of US.. A group was also treated with Cremophor EL suspension containing free PTX and Dox ([PTX] = 4.7 mg / kg, [Dox] = 2.5 mg / kg) (b) Plot of animal weights recorded over the course of the experiment for each group. For graphs (a) and (b) **p < 0.01, ***p < 0.001. Error bars represent \pm SEM where n = 5.